

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Betamethasone (0.05%) Ointment Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil 13106-054

Telephone : +55 (19) 3758-2000

Emergency telephone : +55 (11) 3173-4931

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

Long-term (chronic) aquatic hazard : Category 1

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :

Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.
H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Petrolatum	8009-03-8		≥ 70 -< 90
Propylene glycol monostearate	1323-39-3		≥ 1 -< 5
Betamethasone	378-44-9	Acute toxicity (Inhalation), Category 2 Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland), Category 1 Long-term (chronic) aquatic hazard, Category 1	$\geq 0,025$ -< 0,1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Vapors may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.6	30.09.2023	1681988-00013	Date of first issue: 18.05.2017

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust, fume, gas, mist, vapors or spray.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
Propylene glycol monostearate	1323-39-3	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
Betamethasone	378-44-9	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

Engineering measures : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : ointment

Color : white to off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

Initial boiling point and boiling range : No data available

Flash point : > 93,3 °C

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Vapors may form explosive mixture with air.
Can react with strong oxidizing agents.

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Petrolatum:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Propylene glycol monostearate:

Acute oral toxicity : LD50 (Mouse): > 5.000 mg/kg

Betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l
Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:

Petrolatum:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Propylene glycol monostearate:

Result : No skin irritation

Betamethasone:

Betamethasone (0.05%) Ointment Formulation

Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Petrolatum:**

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Betamethasone:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Petrolatum:**

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative
Remarks : Based on data from similar materials

Betamethasone:

Routes of exposure : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:**Petrolatum:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.6	30.09.2023	1681988-00013	Date of first issue: 18.05.2017

Application Route: Intraperitoneal injection
 Method: OECD Test Guideline 474
 Result: negative
 Remarks: Based on data from similar materials

Betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Test Type: Chromosome aberration test in vitro
 Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
 cytogenetic assay)
 Species: Mouse
 Application Route: Oral
 Result: equivocal

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ
 cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Petrolatum:**

Species : Rat
 Application Route : Ingestion
 Exposure time : 2 Years
 Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**Petrolatum:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening
 test
 Species: Rat
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Skin contact
 Result: negative
 Remarks: Based on data from similar materials

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.6	30.09.2023	1681988-00013	Date of first issue: 18.05.2017

Betamethasone:

Effects on fetal development : Species: Rabbit
 Application Route: Intramuscular
 Developmental Toxicity: LOAEL: 0,05 mg/kg body weight
 Result: Fetotoxicity., Malformations were observed.

Species: Rat
 Application Route: Subcutaneous
 Developmental Toxicity: LOAEL: 0,42 mg/kg body weight
 Result: Malformations were observed.

Species: Mouse
 Application Route: Intramuscular
 Developmental Toxicity: LOAEL: 1 mg/kg body weight
 Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Components:**Betamethasone:**

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Petrolatum:**

Species : Rat
 NOAEL : 5.000 mg/kg
 Application Route : Ingestion
 Exposure time : 2 y

Betamethasone:

Species : Rabbit
 LOAEL : 0.05 %
 Application Route : Skin contact
 Exposure time : 10 - 30 d
 Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
 LOAEL : 0.05 %
 Application Route : Skin contact

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.6	30.09.2023	1681988-00013	Date of first issue: 18.05.2017

Exposure time	:	8 Weeks
Target Organs	:	thymus gland
Species	:	Mouse
LOAEL	:	0.1 %
Application Route	:	Skin contact
Exposure time	:	8 Weeks
Target Organs	:	thymus gland
Species	:	Dog
LOAEL	:	0,05 mg/kg
Application Route	:	Oral
Exposure time	:	28 d
Target Organs	:	Blood, thymus gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Betamethasone:**

Inhalation	:	Target Organs: Adrenal gland
Skin contact	:	Symptoms: Redness, pruritis, Irritation

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Petrolatum:**

Toxicity to fish	:	LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10.000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 10 mg/l Exposure time: 21 d Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Betamethasone (0.05%) Ointment Formulation

Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

Betamethasone:

- Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,052 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
- NOEC (Oryzias latipes (Japanese medaka)): 0,07 µg/l
Exposure time: 219 d
Method: OECD Test Guideline 229
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
- M-Factor (Chronic aquatic toxicity) : 1.000

Persistence and degradability**Components:****Petrolatum:**

- Biodegradability : Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Betamethasone:**

- Partition coefficient: n-octanol/water : log Pow: 2,11

Mobility in soil

No data available

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.6 Revision Date: 30.09.2023 SDS Number: 1681988-00013 Date of last issue: 04.04.2023
Date of first issue: 18.05.2017

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Betamethasone)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Betamethasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.6	30.09.2023	1681988-00013	Date of first issue: 18.05.2017

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone)
Class	:	9
Packing group	:	III
Labels	:	9
Hazard Identification Number	:	90

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.6	30.09.2023	1681988-00013	Date of first issue: 18.05.2017

x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8